Estrella Immunopharma Files 8-K for Other Events
Ticker: ESLAW · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1844417
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Estrella Immunopharma filed an 8-K for 'Other Events' on 9/23/25.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on September 29, 2025, reporting an event that occurred on September 23, 2025. The filing is related to "Other Events" and does not specify any significant financial transactions or corporate changes within the provided text.
Why It Matters
This 8-K filing indicates a reportable event occurred for Estrella Immunopharma, Inc. on September 23, 2025, requiring disclosure to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain specific financial or operational details that would immediately indicate high risk.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- September 23, 2025 (date) — Date of earliest event reported
- September 29, 2025 (date) — Date of report
- TradeUP Acquisition Corp. (company) — Former company name
FAQ
What specific event triggered this 8-K filing for Estrella Immunopharma, Inc. on September 23, 2025?
The provided text states the filing is for 'Other Events' but does not specify the exact nature of the event.
When was this 8-K report officially filed with the SEC?
The report was filed as of date September 29, 2025.
What is Estrella Immunopharma, Inc.'s primary business according to the filing?
The filing lists Estrella Immunopharma, Inc.'s Standard Industrial Classification as 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
What was Estrella Immunopharma, Inc. formerly known as?
The company was formerly known as TradeUP Acquisition Corp.
Where is Estrella Immunopharma, Inc. headquartered?
The company's principal executive address is 5858 Horton Street, Suite 370, Emeryville, California 94608.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-09-29 17:15:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $1.00 — price of the Company's common stock was $1.00 per share or greater. Accordingly, Nasd
- $35,000,000 — s market value of listed securities was $35,000,000 or greater. Accordingly, Nasdaq conside
Filing Documents
- ea0259355-8k_estrella.htm (8-K) — 30KB
- 0001213900-25-093197.txt ( ) — 237KB
- esla-20250923.xsd (EX-101.SCH) — 4KB
- esla-20250923_def.xml (EX-101.DEF) — 26KB
- esla-20250923_lab.xml (EX-101.LAB) — 36KB
- esla-20250923_pre.xml (EX-101.PRE) — 25KB
- ea0259355-8k_estrella_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On September 23, 2025, Estrella Immunopharma, Inc. (the "Company") received two letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained compliance with certain of Nasdaq's continued listing requirements. The first letter confirmed the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 2, 2025, the Company was notified by Nasdaq on April 30, 2025, that it was not in compliance with this requirement. The letter from Nasdaq states that for the 10 consecutive business days from September 9, 2025, through September 22, 2025, the closing bid price of the Company's common stock was $1.00 per share or greater. Accordingly, Nasdaq considers this matter closed. The second letter confirmed the Company has regained compliance with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2025, the Company was notified by Nasdaq on August 1, 2025, that it was not in compliance with this requirement. The letter from Nasdaq states that for the 17 consecutive business days from August 28, 2025, through September 22, 2025, the Company's market value of listed securities was $35,000,000 or greater. Accordingly, Nasdaq considers this matter closed 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Cheng Liu Title: Chief Executive Officer Date: September 29, 2025 2